GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Design Therapeutics
Design Therapeutics is a biotech company developing gene therapy. Its stock price is highly volatile, reflecting the hopes and setbacks of its clinical trials, which is typical for early-stage companies.
Share prices of companies in the market segment - Dna
Design Therapeutics is a biopharmaceutical company developing a new class of small-molecule therapeutics that target the genome to treat genetic diseases. We've classified it in the "DNA" segment. The chart below shows the overall dynamics of the cutting-edge gene medicine sector, which promises to revolutionize the treatment of inherited diseases.
Broad Market Index - GURU.Markets
Design Therapeutics is a biotech company developing a new class of small-molecule drugs that target DNA to treat genetic diseases. As part of the GURU.Markets index, it represents the cutting edge of medicine. The chart below represents the entire market. See how this innovator compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
DSGN - Daily change in the company's share price Design Therapeutics
For Design Therapeutics, a biopharmaceutical company, change_co is a measure of the sector's inherently high volatility. Each daily change reflects sensitivity to news about clinical trials of its platform. This metric isn't just noise, but a critical component of the models on System.GURU.Markets that assess risk in innovative medicine.
Daily change in the price of a set of shares in a market segment - Dna
Design Therapeutics, Inc. is a biotech company. This chart highlights the sector's extreme volatility. Comparison with DSGN, which focuses on treating genetic diseases, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Design Therapeutics is a biopharmaceutical company developing drugs to treat genetic diseases. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing Design's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Design Therapeutics
Design Therapeutics' year-over-year performance is a story of developing a new class of gene therapy. Its 12-month market cap depends entirely on progress in preclinical and early clinical trials. Each successful experiment confirming the potential of its GeneTAC platform is a fundamental step toward value creation.
Annual dynamics of market capitalization of the market segment - Dna
Design Therapeutics, Inc. is an early-stage biotech company developing a new class of drugs based on gene modulation. Its stock price is entirely speculative and based on investor confidence in its breakthrough scientific platform, not on current financial performance.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Design Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Design Therapeutics
The value of Design, a biopharmaceutical company, is speculative. Monthly fluctuations on the chart reflect not revenue, but rather news about the progress of preclinical and clinical trials of its drugs, based on its unique gene therapy technology, which determines its future.
Monthly dynamics of market capitalization of the market segment - Dna
Design Therapeutics is a biotech company developing a new class of drugs ("gene-targeted chimeras") designed to treat genetically determined diseases. This is cutting-edge, but risky, science. The biotech sector chart will reveal investors' overall appetite for breakthrough technologies, which provides a backdrop for assessing the potential of the Design platform.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Design Therapeutics develops gene therapy. This is a cutting-edge, yet risky, sector of biotechnology. The company's shares move not in response to the market, but in anticipation of laboratory breakthroughs. Any news about clinical trials can cause sharp fluctuations, completely ignoring overall economic trends, as reflected in the chart.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Design Therapeutics
Design Therapeutics, a biotech company developing gene therapy, operates at the cutting edge of science. Its weekly stock price is entirely dependent on research progress. Any news, even about preclinical trials, can trigger a sharp reaction from investors assessing its long-term potential.
Weekly dynamics of market capitalization of the market segment - Dna
Biotech companies developing gene therapy, like Design Therapeutics, are at the forefront of science. News in this field often impacts the entire industry. The chart below illustrates this general sentiment. It allows one to assess how promising the market perceives Design Therapeutics' platform compared to competitors' technologies.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Design Therapeutics develops drugs to treat genetic diseases. Like other early-stage biotechs, its shares move not with the market, but on expectations of scientific breakthroughs. The chart will show how unpredictable its weekly performance is and how independent it is of the macroeconomic environment.
Market capitalization of the company, segment and market as a whole
DSGN - Market capitalization of the company Design Therapeutics
Design Therapeutics' market capitalization reflects investors' bets on its innovative platform for treating genetic diseases. The chart shows the market's faith in its approach, which relies on creating small molecules capable of "correcting" genetic defects. Its value, like that of many early-stage biotechs, reflects scientific potential rather than current revenue.
DSGN - Share of the company's market capitalization Design Therapeutics within the market segment - Dna
Design Therapeutics is a biotechnology company developing drugs based on genetic technologies. In the innovative DNA therapeutics segment, its market capitalization reflects investors' faith in its scientific platform. Fluctuations in this indicator reflect the market's reaction to any news regarding the progress of preclinical and clinical trials.
Market capitalization of the market segment - Dna
This chart shows the total value of the entire biotech sector focused on gene therapy. This is the cutting edge of science. For Design Therapeutics, which is developing a new generation of gene "editing," the rise in this chart signifies an influx of capital and investor confidence that genetic diseases can be treated, not just the symptoms.
Market capitalization of all companies included in a broad market index - GURU.Markets
Design Therapeutics develops drugs targeting the genetic causes of disease. Its market value represents another bet on gene therapy. Overall, it represents the market share that is willing to allocate to cutting-edge scientific approaches to DNA repair.
Book value capitalization of the company, segment and market as a whole
DSGN - Book value capitalization of the company Design Therapeutics
Design Therapeutics is a biotech company developing gene therapy. Its book value is a combination of its scientific and financial capital. It consists of cash for R&D and the value of its proprietary GeneTAC platform. How has this capital changed as the technology has developed? The chart below illustrates this trend.
DSGN - Share of the company's book capitalization Design Therapeutics within the market segment - Dna
Design Therapeutics develops drugs to treat genetic diseases. Its innovative approach requires a substantial resource base: cutting-edge laboratories and a proprietary platform for developing small molecules that interact with DNA. The chart shows the company's share of the physical R&D infrastructure required for gene therapy.
Market segment balance sheet capitalization - Dna
Design Therapeutics, a development-stage biopharmaceutical company, has minimal physical assets. Its business is focused on R&D. The BCap_Seg chart for the biotech sector, which consists of hundreds of similar companies, is generally low, as its primary capital is intellectual property.
Book value of all companies included in the broad market index - GURU.Markets
Design Therapeutics' capital comes not from its manufacturing facilities, but from its GeneTAC™ scientific platform for creating DNA-targeted drugs. Its book value reflects investments in research and patents. The chart shows how this science-intensive asset, aimed at the future of genetic medicine, compares to traditional pharmaceuticals.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Design Therapeutics
Design Therapeutics' balance sheet is its R&D capital. Its entire market value is a premium for its GeneTAC™ scientific platform. The graph represents investors' bet that this technology will be able to create new drugs for the treatment of genetic diseases.
Market to book capitalization ratio in a market segment - Dna
Design Therapeutics is a biotech company developing a new class of gene therapy. Its high valuation on this chart is a clear bet on the breakthrough potential of its scientific platform, despite the lack of revenue and products on the market. Investors are buying into the future.
Market to book capitalization ratio for the market as a whole
Design Therapeutics is a biotech company developing gene therapy. Its market value is based on the potential of its scientific platform. Like many early-stage companies, its valuation reflects investors' bets on a future scientific breakthrough, not on its current assets.
Debts of the company, segment and market as a whole
DSGN - Company debts Design Therapeutics
Design Therapeutics, a biotech company developing gene therapy, is in early-stage research. All capital raised, including potential debt instruments, is allocated to preclinical and early clinical trials. This chart shows how the company funds its scientific hypotheses, which represent high-risk investments in the future of medicine.
Market segment debts - Dna
Design Therapeutics is a biotech company developing a new generation of gene therapy-based drugs. At the preclinical and early clinical trial stages, such companies are entirely dependent on equity capital. Raising debt is unlikely and risky. This chart clearly illustrates the financial strategy typical of innovative biotech companies.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Design Therapeutics
Design Therapeutics is a biotech company developing DNA-based drugs. Its entire business is a major investment in science with a long-term payback horizon. This graph shows how dependent it is on external funding. It reflects the high level of risk inherent in cutting-edge pharmaceutical research.
Market segment debt to market segment book capitalization - Dna
Design Therapeutics is developing a new class of drugs capable of correcting genetic mutations. This is a cutting-edge, yet highly risky, area of biotechnology. The chart shows how aggressively the sector uses debt to finance revolutionary scientific approaches, providing context for assessing the company's potential and risks.
Debt to book value of all companies in the market
Design Therapeutics operates in the cutting-edge field of gene therapy, where scientific development requires massive, long-term investments. This chart, showing the market's debt-to-book ratio, provides context for the valuation. It helps understand how the company finances its expensive research and compares its strategy with other innovative biotech companies.
P/E of the company, segment and market as a whole
P/E - Design Therapeutics
Design Therapeutics is a biopharmaceutical company developing a new class of genomic drugs to treat diseases caused by nucleotide repeats. This chart shows the company's price-to-earnings ratio, which is currently irrelevant. The valuation is based solely on its belief in its scientific platform and the potential to achieve breakthroughs in genetic medicine.
P/E of the market segment - Dna
Design Therapeutics develops gene therapy. This chart shows the average valuation for the biotech sector. It emphasizes that Design's valuation is based not on current earnings, but on the highest expectations for its scientific platform, making a direct P/E comparison with the industry a measure of confidence in its future breakthroughs.
P/E of the market as a whole
Design Therapeutics is a biopharmaceutical company developing a new generation of small-molecule drugs that directly target DNA and RNA to treat genetic diseases. This chart reflects investors' overall risk appetite. It helps us understand whether DSGN's high valuation is based on faith in its breakthrough scientific platform or whether it's driven by overall biotech sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Design Therapeutics
Design Therapeutics is a biotech company developing drugs to treat genetic diseases. Its future profitability depends on the success of its innovative GeneTAC platform. This chart shows speculative market expectations regarding the potential of its technology and future clinical trial results.
%20P%2FE%20Design%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Design-Therapeutics&v=1772608428280 "Chart of the company's future (projected) P/E Design Therapeutics")
Future (projected) P/E of the market segment - Dna
Design Therapeutics is a biotech company developing a new class of "gene-targeted chimeras" (GeneTACs) for the treatment of genetic diseases. The data here reflects the collective bet of analysts on the success of its innovative scientific platform. It is a barometer of expectations for whether its approach will lead to the creation of effective drugs.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Dna&v=1772608428340 "Future (projected) P/E graph of the market segment - Dna")
Future (projected) P/E of the market as a whole
Design Therapeutics is developing a new class of drugs that target DNA. This is at the cutting edge of science. This sentiment chart shows how willing investors are to invest in fundamental research, which can take years but, if successful, will revolutionize medicine.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772608428417 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Design Therapeutics
Design Therapeutics is a biotech company developing a new class of drugs that can directly target DNA to treat genetic diseases. This chart shows the financial impact of breakthrough research. It reflects investment in a platform that, if successful, could lead to a range of new therapies.
Profit of companies in the market segment - Dna
Design Therapeutics is a biopharmaceutical company developing drugs based on genetic technologies. Being in the early stages of research, the company is not yet profitable, but is investing in its scientific platform. Its prospects are tied to breakthroughs in gene therapy, reflecting the long-term and capital-intensive nature of this cutting-edge biotechnology segment.
Overall market profit
Design Therapeutics is a biotech company developing a new generation of gene therapy-based drugs. Its valuation is entirely dependent on the success of clinical trials. While there's no direct correlation with the economy, the overall market sentiment, as reflected in this chart, influences the company's ability to raise the significant capital needed to advance its developments.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Design Therapeutics
Design Therapeutics is a biotech company developing a new class of drugs based on small molecules that interact with genes. This chart reflects analysts' speculative revenue expectations. The forecast is entirely dependent on the success of preclinical and clinical trials of their innovative GeneTAC platform.
%20profit%20of%20the%20company%20Design%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Design-Therapeutics&v=1772608428650 "Graph of future (projected) profit of the company Design Therapeutics")
Future (predicted) profit of companies in the market segment - Dna
Design Therapeutics is a biotech company developing a new class of drugs that directly interact with genes. The pharmaceutical industry profit projections shown in the graph reflect the interest in gene therapy. This chart helps us understand how revolutionary Design's technology could be if its clinical trials are successful.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Dna&v=1772608428668 "Graph of future (predicted) profits of companies in a market segment - Dna")
Future (predicted) profit of the market as a whole
Design Therapeutics is a biotech company developing gene therapy. Its success depends on the results of clinical trials and its ability to attract significant investment. The overall economic climate, reflected in this chart, influences investor risk appetite and the availability of capital for innovative but long-term biotech projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772608428696 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Design Therapeutics
Design Therapeutics is a biopharmaceutical company developing a new class of drugs based on genetic technologies for the treatment of inherited diseases. It may not have current revenue. This chart shows how the market values its innovative scientific platform and potential for creating breakthrough treatments.
P/S market segment - Dna
Design Therapeutics is a biopharmaceutical company developing a new generation of drugs that directly target the genome to treat genetic diseases. This chart shows the average revenue estimate in the biotech sector. It helps understand the premium investors are placing on the company's cutting-edge gene technologies.
P/S of the market as a whole
Design Therapeutics is a biotech company developing a new class of drugs called GeneTACs for the treatment of genetic diseases. The company is in early-stage research. This chart shows the average market valuation of companies based on current revenue, providing context for the valuation of innovative but currently unprofitable biotechs.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Design Therapeutics
Design Therapeutics is a biotech company developing a new class of drugs that directly interact with genes. This chart reflects investors' high estimates of potential future revenue. This valuation is a bet on the breakthrough nature of its GeneTAC platform and its application in the treatment of genetic diseases.
%20P%2FS%20Design%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Design-Therapeutics&v=1772608428830 "The graph of the company's future (projected) P/S Design Therapeutics")
Future (projected) P/S of the market segment - Dna
Design Therapeutics is a biopharmaceutical company developing a new generation of small-molecule therapeutics that target the genome. This chart compares market expectations for its future revenue with other companies in the DNA technology sector. This valuation reflects investors' belief in the breakthrough potential of its GeneTAC platform for treating genetic diseases.
%20P%2FS%20market%20segment%20graph%20-%20Dna&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Dna&v=1772608428888 "Future (projected) P/S market segment graph - Dna")
Future (projected) P/S of the market as a whole
Design Therapeutics is a biotechnology company developing next-generation drugs to treat genetic diseases. Its value is based on the potential of its unique scientific platform. This chart of overall market expectations for Design Therapeutics is merely a backdrop, as its future is determined by the success of preclinical and clinical trials, not economics.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772608428996 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Design Therapeutics
This chart illustrates the revenue of Design Therapeutics, a biotech company developing gene therapy drugs for the treatment of inherited diseases. Being in the preclinical and early clinical stages, the company has no sales revenue. The chart reflects this reality: the focus is entirely on science, and funding comes from investors in anticipation of a future breakthrough.
Sales of companies in the market segment - Dna
Design Therapeutics is a biopharmaceutical company developing a new class of drugs, called GeneTAC™, to treat genetic diseases by directly targeting DNA. This chart shows revenue in the DNA therapeutics sector. It reflects the cutting edge of gene medicine and the enormous potential of technologies capable of correcting genetic defects at a fundamental level.
Overall market sales
Design Therapeutics is a biotechnology company developing gene therapy for the treatment of inherited diseases. Its value is determined by progress in clinical trials. The overall economic situation, reflected in this chart, does not directly affect demand, but it does create a backdrop for attracting investment and influences the future ability of the healthcare system to pay for expensive gene therapies.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Design Therapeutics
Design Therapeutics is a biotechnology company developing a new generation of gene-targeted therapies. This revenue projection chart is purely speculative. Its dynamics reflect analysts' confidence in the scientific viability of its innovative GeneTAC platform and the potential of its developments in the earliest, preclinical stages of research.
%20sales%20of%20the%20company%20Design%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Design-Therapeutics&v=1772608429183 "Schedule of future (projected) sales of the company Design Therapeutics")
Future (projected) sales of companies in the market segment - Dna
Design Therapeutics is a biopharmaceutical company developing a new class of "gene-targeted chimeras" (GeneTAC™) for the treatment of genetic diseases. Their technology is aimed at correcting errors at the DNA level. This chart shows projected revenues for the entire DNA therapeutics sector, reflecting the enormous expectations for breakthrough genome editing technologies.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Dna&v=1772608429212 "Schedule of future (projected) sales of companies in the market segment - Dna")
Future (projected) sales of the market as a whole
Design Therapeutics is a biotechnology company developing gene therapy. Its potential lies in scientific innovation. Although its activities are not directly linked to economic cycles, positive market forecasts create a favorable environment for attracting the capital needed for expensive research and development in the field of genetics.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772608429272 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Design Therapeutics
Design Therapeutics is a biotech company developing a new class of DNA-targeting drugs. Its financial story is still being written. This chart illustrates the cost of cutting-edge scientific research. It shows the amount of investment the company is devoting to development, on the path to a potential scientific breakthrough.
Market segment marginality - Dna
Design Therapeutics is a biopharmaceutical company developing a new class of drugs based on the GeneTAC technology for the treatment of genetic diseases. This chart compares its operating efficiency with other biotech companies in development. Its competitive advantage may be due to upfront payments from partners or more cost-effective research.
Market marginality as a whole
Design Therapeutics is a biotech company developing next-generation drugs to treat genetic diseases. Its success depends entirely on scientific breakthroughs and clinical trial results, not on the general economic cycles reflected in this chart. The need to treat serious inherited diseases is a constant and powerful driver of their research.
Employees in the company, segment and market as a whole
Number of employees in the company Design Therapeutics
Design Therapeutics is a biotech company developing a new class of drugs to treat genetic diseases. This graph shows a very small team of scientists. For a preclinical-stage company, the size of its staff reflects its focus on fundamental research. Growth will signal a successful transition to clinical trials.
Share of the company's employees Design Therapeutics within the market segment - Dna
Design Therapeutics is a biotech company developing gene-targeted drugs. Being in early-stage research, its team consists of a small group of highly qualified scientists. This graph illustrates its focus on science: the minimal number of employees reflects the fact that its primary asset is cutting-edge research, not manufacturing capacity.
Number of employees in the market segment - Dna
Design Therapeutics is a biotechnology company developing a new class of drugs based on small molecules capable of interacting with genes. This graph reflects the early, research-intensive stage of development. The small staff, comprised primarily of geneticists and chemists, is focused on preclinical research, and its growth will depend on the success of this innovative platform.
Number of employees in the market as a whole
Design Therapeutics is a biotech company developing a new class of DNA-targeting drugs. Its staff includes a cutting-edge scientific team. This overall employment chart serves as a backdrop, highlighting how cutting-edge companies operate within their own paradigm: their growth depends on breakthroughs in the lab, not the general labor market.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Design Therapeutics (DSGN)
Design Therapeutics is a biotech company developing a new class of gene-targeted drugs for the treatment of inherited diseases. Its entire value lies in its scientific potential. This chart shows its enormous market capitalization per employee. This demonstrates that investors value intellectual property and breakthrough technologies, not current operations.
%20of%20the%20company%20Design%20Therapeutics%20(DSGN)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Design-Therapeutics-DSGN&v=1772608429622 "Chart of market capitalization per employee (in thousands of dollars) of the company Design Therapeutics (DSGN)")
Market capitalization per employee (in thousands of dollars) in the market segment - Dna
Design Therapeutics is a biotechnology company developing small-molecule gene therapies. For a research-intensive early-stage company, this metric is a bet on the future. It reflects how highly investors value the scientific platform and the potential discoveries being made by a small but highly skilled team of researchers.
%20by%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Dna&v=1772608429715 "Market capitalization per employee (in thousands of dollars) by market segment - Dna")
Market capitalization per employee (in thousands of dollars) for the overall market
Design Therapeutics is a biopharmaceutical company working on gene therapy. This metric reflects a business at the cutting edge of science. Its market capitalization is based entirely on the promise of its research platform. Even a small team of scientists can be worth hundreds of millions if their technology is recognized as promising.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772608429819 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Design Therapeutics (DSGN)
Design Therapeutics is a biotech company working on a new class of drugs (GeneTACs) that target DNA. It's an early, preclinical stage company. They are not and cannot be profitable. This graph shows the loss per employee. This is the cost of cutting-edge science. It reflects how much capital each scientist in the lab spends on creating future drugs.
%20Chart%20Design%20Therapeutics%20(DSGN)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Design-Therapeutics-DSGN&v=1772608429901 "Company Profit Per Employee (in thousands of dollars) Chart Design Therapeutics (DSGN)")
Profit per employee (in thousands of dollars) in the market segment - Dna
Design Therapeutics is a preclinical biotech company developing gene-targeted drugs. "Profit" here is a negative value (R&D expenses). This metric reflects the capital burn rate per employee. For a company at such an early stage, this is a pure indicator of expenses on fundamental research.
%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Dna&v=1772608429953 "Chart of profit per employee (in thousands of dollars) in the market segment - Dna")
Profit per employee (in thousands of dollars) for the market as a whole
Design Therapeutics is a biotech company developing DNA-targeting drugs. These drugs are in the preclinical or early clinical stages. This chart does not reflect revenue, but rather the cost of research. The negative value per employee represents the capital required to fund the research team in their search for new treatments.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772608430042 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Design Therapeutics (DSGN)
Design Therapeutics is a biotech company developing drugs based on genetic technologies. This schedule is typical for an early-stage company. The lack of revenue per employee means all efforts and capital are focused on research and preclinical trials.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Design-Therapeutics-DSGN&v=1772608430125 "Sales chart per company employee Design Therapeutics (DSGN)")
Sales per employee in the market segment - Dna
Design Therapeutics (DSGN) is a biotech company developing a new generation of gene-targeted therapeutics (GeneTACs) for the treatment of genetically determined diseases. This chart shows the revenue (if any) generated by each employee (scientist). It reflects the productivity of their early-stage R&D platform compared to other biotechs in the gene therapy field.
Sales per employee for the market as a whole
Design Therapeutics is a biopharmaceutical company developing a new class of gene-targeted drugs (GeneTAC™) for the treatment of genetic diseases. This is an early-stage, deep R&D company. The company has no commercial revenue, so its revenue metric is currently close to zero. Its future growth will depend on the success of its innovative platform.
Short shares by company, segment and market as a whole
Shares shorted by company Design Therapeutics (DSGN)
Design Therapeutics is a biotech company developing genetically engineered drugs. This chart reflects bearish sentiment. This is a classic bet against biotech: bears expect the company's expensive research to fail to produce an approved drug, leading to a burnout of all capital.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Design-Therapeutics-DSGN&v=1772608430288 "Short Shares Chart for the Company Design Therapeutics (DSGN)")
Shares shorted by market segment - Dna
Design Therapeutics is a biotech company developing drugs targeting the genetic causes of diseases. This chart shows bearish bets. "Shorting" early-stage biotech is a bet that their complex scientific platform won't work in practice or that their trials will fail.
Shares shorted by the overall market
Design Therapeutics is a company developing gene therapy by "editing" DNA to treat hereditary diseases. It's pure science and high risk. This chart shows the level of general market fear. When it rises, investors prefer a bird in the hand, dumping stocks of the "future" that require years and millions of dollars in research.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Design Therapeutics (DSGN)
Design Therapeutics is a clinical-stage biotech. Its shares are extremely sensitive to trial news. This chart can surge above 70 on positive R&D data. Oversold territory (<30) often reflects research setbacks, funding concerns, or general risk aversion.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Design-Therapeutics-DSGN&v=1772608430382 "RSI 14 indicator chart for the company's stock Design Therapeutics (DSGN)")
RSI 14 Market Segment - Dna
Design Therapeutics (DSGN) is a biotech company working on gene silencing (GeneTAC) to treat inherited diseases. The RSI_14_Seg for "Dna" (biotech) reflects the overall sentiment in the sector. The chart helps us understand: is DSGN's volatility a reaction to their trials, or is the entire sector overheated?
RSI 14 for the overall market
Design Therapeutics (DSGN) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast DSGN (Design Therapeutics)
Design Therapeutics (DSGN) is a biotech company developing gene-targeted chimeras (GeneTACs) to treat genetic diseases. This chart shows the average 12-month forecast. It reflects analysts' confidence in this innovative scientific platform and early preclinical data.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-DSGN-Design-Therapeutics&v=1772608430501 "A chart showing analyst consensus forecasts for the expected stock price. DSGN (Design Therapeutics)")
The difference between the consensus estimate and the actual stock price DSGN (Design Therapeutics)
Design Therapeutics is an early-stage biotech company developing a novel GeneTACs platform for the treatment of genetically determined diseases. This chart reflects analysts' highly speculative expectations regarding their unproven scientific platform and the chances of success in future clinical trials.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-DSGN-Design-Therapeutics&v=1772608430563 "A chart showing the difference between the consensus forecast and the actual stock price. DSGN (Design Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Dna
Design Therapeutics is a biotech company developing a new generation of small-molecule gene therapy (pills) for the treatment of inherited diseases. This chart shows analysts' overall expectations for the DNA technology sector. It reflects whether experts believe this innovative R&D platform can deliver breakthroughs.
Analysts' consensus forecast for the overall market share price
Design Therapeutics (DSGN) is a biopharmaceutical company developing "gene therapy 2.0." They create small molecules that can "edit" gene expression rather than replace them. This chart shows the overall risk appetite of Design Therapeutics. It reflects the market's willingness to fund breakthrough, but extremely risky and long-term research platforms.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Design Therapeutics
Design Therapeutics is a preclinical-stage biotech company. Their value lies in their scientific platform (GeneTACs), which is a new approach to gene regulation (as opposed to editing). This graph represents pure R&D betting. It likely reflects the market's faith in their breakthrough but risky science, their cash reserves, and their early lab data.
AKIMA Market Segment Index - Dna
Design Therapeutics (DSGN) is a clinical-stage biotech and a pioneer in gene therapy; the company is developing an innovative platform (GeneTAC) for the treatment of rare genetic diseases. This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does this breakthrough (R&D platform) model (DSGN) differentiate it from the average pharma company?
The AKIM Index for the overall market
Design Therapeutics is a biotech company developing a new class of small molecules (GeneTAC) for the treatment of genetic diseases (Friedreich's ataxia). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this scientific platform, targeting the cause of the disease, compares to overall economic trends.
